TPM3 and cancer: Pan‐TRK IHC can serve as a screening method in cancer types with a low mutational frequency for NTRK gene fusion, not expressing NTRK, when a DNA‐based NGS panel test is not commonly performed. Also, pan‐TRK IHC can serve as a re‐evaluation method for NGS tests